Wedbush Predicts Reduced Earnings for Replimune Group

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Research analysts at Wedbush cut their FY2025 earnings estimates for shares of Replimune Group in a note issued to investors on Wednesday, February 12th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($3.07) per share for the year, down from their prior estimate of ($2.91). The consensus estimate for Replimune Group's current full-year earnings is ($2.97) per share. Wedbush also issued estimates for Replimune Group's Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.93) EPS.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09).

A number of other equities research analysts also recently weighed in on the stock. BMO Capital Markets upped their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. HC Wainwright increased their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $19.29.

Replimune Group Price Performance

Shares of Replimune Group stock traded up $0.53 during trading on Monday, hitting $14.31. The stock had a trading volume of 1,031,331 shares, compared to its average volume of 750,465. The business has a fifty day moving average of $12.61 and a two-hundred day moving average of $11.81. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The firm has a market cap of $1.10 billion, a P/E ratio of -4.66 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Sterling Capital Management LLC grew its stake in shares of Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd lifted its stake in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after purchasing an additional 8,183 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Replimune Group in the 4th quarter worth approximately $117,000. Finally, Quantinno Capital Management LP bought a new position in shares of Replimune Group in the fourth quarter valued at approximately $127,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 8.80% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.